Loading...

Paradigm Biopharmaceuticals Limited

PAR.AXASX
Healthcare
Biotechnology
$0.16
$-0.01(-5.88%)
Australian Market is Open • 13:36

Paradigm Biopharmaceuticals Limited (PAR.AX) Stock Competitors & Peer Comparison

See (PAR.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
PAR.AXA$0.17+0.00%73.7M-1.70-A$0.10N/A
CSL.AXA$97.71-0.26%46.1B11.15A$8.63+4.43%
TLX.AXA$14.10-4.25%4.8B-475.33-A$0.03N/A
MSB.AXA$2.06-2.61%2.6B-20.40-A$0.10N/A
NEU.AXA$12.53-2.03%1.6B53.70A$0.23N/A
CU6.AXA$2.63-9.31%967.9M-9.29-A$0.28N/A
OPT.AXA$0.60+0.00%820.8M-1.40-A$0.43N/A
PYC.AXA$1.35-5.59%772.5M-16.56-A$0.08N/A
RAC.AXA$2.60-5.80%488.3M-52.20-A$0.05N/A
CUV.AXA$9.22-2.64%460.3M14.27A$0.64+0.55%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

PAR.AX vs CSL.AX Comparison May 2026

PAR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PAR.AX stands at 73.7M. In comparison, CSL.AX has a market cap of 46.1B. Regarding current trading prices, PAR.AX is priced at A$0.17, while CSL.AX trades at A$97.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PAR.AX currently has a P/E ratio of -1.70, whereas CSL.AX's P/E ratio is 11.15. In terms of profitability, PAR.AX's ROE is -2.66%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, PAR.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAR.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions